Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVCR
stocks logo

NVCR

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
153.87M
+2.34%
-0.390
+25.81%
156.92M
+1.17%
-0.428
+52.97%
160.35M
-0.57%
-0.517
-15.3%
Estimates Revision
The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 1.67% over the past three months. During the same period, the stock price has changed by -18.87%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-18.4%
In Past 3 Month
Stock Price
Go Down
down Image
-18.87%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 34.00 USD with a low forecast of 27.00 USD and a high forecast of 40.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
up Image0
Current: 17.890
sliders
Low
27.00
Averages
34.00
High
40.00
up Image0
Current: 17.890
sliders
Low
27.00
Averages
34.00
High
40.00
Piper Sandler
Jason Bednar
Buy
Maintains
$42 → $34
2025-04-23
Reason
Piper Sandler
Jason Bednar
Price Target
$42 → $34
2025-04-23
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on Novocure to $34 from $42 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping. Piper thinks an in-line quarter for GBM is on tap, particularly as performance ex-France has been fairly mediocre for several quarters running. Ramping of NSCLC - both Rx and active patients - may prove to be the bigger influencer on stock performance, and the firm believes investor skepticism on success in NSCLC makes for a positive setup heading into this week's result.
Wedbush
David Nierengarten
Hold
Maintains
$29 → $27
2025-04-16
Reason
Wedbush
David Nierengarten
Price Target
$29 → $27
2025-04-16
Maintains
Hold
Reason
Wedbush lowered the firm's price target on Novocure to $27 from $29 and keeps a Neutral rating on the shares ahead of quarterly results. The firm expects continued modest growth in the core Optune GBM franchise. The company expects net revenue growth to better reflect the growth in active patients in 2025, which management forecasts will be in the low to mid-single digits. Wedbush continues to hold the view that any meaningful growth must come from indications outside GBM.
JP Morgan
Jessica Fye
Hold
Maintains
$29 → $28
2025-04-10
Reason
JP Morgan
Jessica Fye
Price Target
$29 → $28
2025-04-10
Maintains
Hold
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$38
2025-01-14
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$38
2025-01-14
Reiterates
Strong Buy
Reason
Piper Sandler
Jason Bednar
Buy
Maintains
$28 → $42
2024-12-13
Reason
Piper Sandler
Jason Bednar
Price Target
$28 → $42
2024-12-13
Maintains
Buy
Reason
Piper Sandler raised the firm's price target on Novocure to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more favorably for medical technology investors that can better handicap upcoming "medtech-like" milestones for the company, including new indication commercialization, regulatory submission and approvals, and securing payer coverage. Piper introduced estimates through 2028 and highlights the company's improved execution for four consecutive quarters.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$30 → $38
2024-12-03
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$30 → $38
2024-12-03
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novocure Ltd (NVCR.O) is -9.84, compared to its 5-year average forward P/E of 33.42. For a more detailed relative valuation and DCF analysis to assess Novocure Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
33.42
Current PE
-9.84
Overvalued PE
483.68
Undervalued PE
-416.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-103.11
Current EV/EBITDA
-11.41
Overvalued EV/EBITDA
247.98
Undervalued EV/EBITDA
-454.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
13.55
Current PS
3.18
Overvalued PS
23.21
Undervalued PS
3.90

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NVCR News & Events

Events Timeline

(ET)
2025-04-24
12:20:35
Novocure's NSCLC launch momentum 'positive,' says H.C. Wainwright
select
2025-04-24
07:04:23
Novocure reports Q1 EPS (31c), consensus (46c)
select
2025-04-23 (ET)
2025-04-23
10:16:59
Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.5
05-16WSJ
The Next Frontier to Treat Cancer: Electricity

  • Electricity as a Treatment: Electricity is being explored as a potential treatment for various diseases, including rheumatoid arthritis and challenging cancers like glioblastoma and pancreatic cancer.

  • Advancements in Medical Technology: New technologies are expanding the use of electric fields and pulses in medicine, building on established treatments like pacemakers and electroconvulsive therapy.

Preview
7.0
04-25Benzinga
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

  • Financial Performance: NovoCure Ltd reported a first-quarter 2025 loss of 31 cents, an improvement from the previous year's 36-cent loss, with sales rising 12% to $155 million, surpassing expectations.

  • Tariff Impact and Product Updates: The company is monitoring changes in the global tariff environment that could affect import duties by up to $11 million in 2025, while also noting a decrease in prescriptions for Optune Gio and receiving CE Mark approval for Optune Lua for specific lung cancer treatments.

Preview
7.0
04-24SeekingAlpha
Novocure outlines expansion plans for lung cancer treatment and regulatory milestones in 2025

  • Management Insights: NovoCure's Q1 2025 earnings call highlighted the company's transition to a multi-indication oncology firm, with significant advancements including European CE Mark approval for Optune Lua in NSCLC and a focus on expanding its market presence, particularly in Germany and Japan.

  • Financial Performance and Outlook: The company reported $155 million in net revenue for Q1 2025, marking a 12% year-over-year increase, while also facing challenges such as tariff uncertainties and the need for broader payer coverage for NSCLC, which could impact future growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novocure Ltd (NVCR) stock price today?

The current price of NVCR is 17.89 USD — it has increased 1.71 % in the last trading day.

arrow icon

What is Novocure Ltd (NVCR)'s business?

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

arrow icon

What is the price predicton of NVCR Stock?

Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 34.00 USD with a low forecast of 27.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novocure Ltd (NVCR)'s revenue for the last quarter?

Novocure Ltd revenue for the last quarter amounts to 154.99M USD, increased 11.91 % YoY.

arrow icon

What is Novocure Ltd (NVCR)'s earnings per share (EPS) for the last quarter?

Novocure Ltd. EPS for the last quarter amounts to -0.31 USD, decreased -13.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novocure Ltd (NVCR)'s fundamentals?

The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 1.67% over the past three months. During the same period, the stock price has changed by -18.87%.
arrow icon

How many employees does Novocure Ltd (NVCR). have?

Novocure Ltd (NVCR) has 1453 emplpoyees as of May 17 2025.

arrow icon

What is Novocure Ltd (NVCR) market cap?

Today NVCR has the market capitalization of 1.99B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free